Czech drugmaker Zentiva has called a special shareholders meeting Sept. 3 to consider Sanofi-Aventis' buyout offer--and to consider competing bids. Last month, Zentiva management told shareholders to reject the $1.86 billion bid because it didn't adequately reflect the company's value. Report